Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Stanford University National Cancer Institute (NCI) |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00186316 |
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Biological: Idiotype-pulsed allogeneic dendritic cells |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells |
Estimated Enrollment: | 30 |
Study Start Date: | April 2003 |
To evaluate feasibility and safety of vaccination with allogeneic idiotype-pulsed dendritic cells following mixed chimeric allogeneic transplantation for multiple myeloma.
Ages Eligible for Study: | 17 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:1. For specimen collection and idiotype protein development:
Karnofsky performance status of 70 or greater
2. For Vaccination:
Donor Inclusion Criteria (allodonor is the same donor used for non-myeloablative transplant)
Exclusion Criteria:1. For specimen collection and idiotype protein development:
Subjects with prognosis < 6 months
2. For Vaccination:
thalidomide)
Any patient on more than two of the following immunosuppressive agents or at a dose greater than that indicated for a single immunosuppressive agent:
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Ronald Levy | Stanford University |
Study ID Numbers: | BMT155, 79000, BMT155, NCT00186316 |
Study First Received: | September 13, 2005 |
Last Updated: | October 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00186316 History of Changes |
Health Authority: | United States: Institutional Review Board; United States: Food and Drug Administration |
Immunoproliferative Disorders Immunologic Factors Immunoglobulin Idiotypes Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Antibodies Hemorrhagic Disorders Lymphoproliferative Disorders Immunoglobulins Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Immunoproliferative Disorders Immunologic Factors Immunoglobulin Idiotypes Immune System Diseases Blood Protein Disorders Hematologic Diseases Physiological Effects of Drugs Vascular Diseases |
Paraproteinemias Hemostatic Disorders Pharmacologic Actions Multiple Myeloma Neoplasms Hemorrhagic Disorders Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |